Canterbury DHB

Context

Tumour Lysis Syndrome (TLS)

As tumour cells turn over or are broken down by therapies they release potassium, phosphate and nucleic acids to the circulation. The nucleic acids are broken down to uric acid which can deposit as crystals in the renal tubules. The phosphate can bind to calcium and then deposit in both the renal tubules and the heart, causing arrhythmias.

Some tumour-related factors are associated with high risk TLS:

Some clinical features also predispose to TLS:

For a review of tumour lysis syndrome, see Will, A. and E. Tholouli (2012). "The clinical management of tumour lysis syndrome in haematological malignancies." British Journal of Haematology 154(1): 3-13.

In This Section

Prophylaxis

Management of Tumour Lysis Syndrome

About this Canterbury DHB document (5734):

Document Owner:

Sean Macpherson (see Who's Who)

Issue Date:

January 2019

Next Review:

January 2022

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5734